Masimo Stock News

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.

Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.

Masimo (MASI) reported earnings 30 days ago. What's next for the stock?

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road

Masimo Corporation (NASDAQ:MASI) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.34% to the previous day’s close as strong demand from buyers drove the stock to $136.72. Actively observing the price movement in the last trading, the stock closed the session at $141.44, falling within a range of $136.59 and … In 2022, Will Masimo Corporation (NASDAQ: MASI) Be Bullish Or Bearish? Read More »

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

The FDA has FDA cleared Masimo Corp''s (NASDAQ: MASI ) SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. SedLine helps clinicians monitor brain activity bilaterally by processing electroencephalogram (EEG) signals from Masimo''s four-lead SedLine EEG sensors. This clearance brings Masimo''s bilateral brain activity monitoring to … Full story available on Benzinga.com

IRVINE, Calif.--(BUSINESS WIRE)--The pediatric indication and pediatric EEG sensor for Masimo SedLine® Brain Function Monitoring have received FDA clearance.

Masimo Corp (MASI) shares closed this week 33.2% lower than it did at the end of last week. The stock is currently down 47.3% year-to-date, down 42.0% over the past 12 months, and up 83.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $232.89 and as low as $133.94 this week.Shares closed 49.4% below its 52-week high and 15.2% above its 52-week low.Trading volume this week was 62.4% higher than the 10-day average and 238.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 14.7% lower than its 5-day moving average, 26.7% lower than its 20-day moving average, and 41.5% lower than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 557.8% The company's stock price performance over the past 12 months lags the peer average by -431.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -32.2% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

After a loss of more than a third on Wednesday, Masimo <> shares continue to trade higher for the second straight session buoyed by an upgrade at Needham, which calls the selloff…

Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE: DEN ) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $91.30 and a 52-week-low of $37.00. At the end of the last trading period, Denbury closed at $66.56. For Pilgrims Pride Corp (NASDAQ: PPC ), Stephens & Co. upgraded the previous rating of Equal-Weight to Overweight. In the fourth quarter, Pilgrims Pride showed an EPS of $0.56, compared to $0.25 from the year-ago quarter. The current stock performance of Pilgrims Pride shows a 52-week-high of $29.70 and a 52-week-low of $20.32. Moreover, at the end of the last trading period, the closing price was at $27.83. According to Scotiabank, the prior rating for Marathon Oil Corp (NYSE: MRO ) was changed from Sector Perform to Sector Outperform. For the fourth quarter, Marathon Oil had an EPS of $0.77, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $22.56 and a 52-week-low of $9.11.

Needham has upgraded Masimo Corp (NASDAQ: MASI ) to Buy from Hold with a $205 price target . According to analyst Mike Matson, the selloff in the stock following the company''s Sound United acquisition was "overdone" as the deal should prove to be highly accretive to earnings. On 16 February, Masimo shares closed 37% lower at $144.62. Related: Masimo Stock … Full story available on Benzinga.com